Back to search results

Hydrogen Gas for Cardiac Arrest with ECPR

This study is testing if giving hydrogen gas (2%) is safe and possible for patients who have had a cardiac arrest and need ECPR (Extracorporeal Cardiopulmonary Resuscitation, a type of life support). Patients admitted to the cardiac intensive care unit with heart problems like congenital heart disease or myocarditis may be eligible. The study aims to see if hydrogen gas, given through a ventilator and ECMO membrane for 72 hours, can help reduce damage after blood flow returns. This study is currently unclear on its status and plans to enroll 53 participants.

Study design
This interventional study will compare usual care to usual care plus hydrogen gas in patients undergoing ECPR. Patients will be randomly assigned to one of these groups.
What's involved
Patients will receive hydrogen gas for 72 hours via a ventilator and ECMO membrane, or usual care. Oxygen levels will be adjusted by the clinical team.
Compensation
Not stated in the trial record.
Follow-up
The safety of hydrogen administration will be measured at 30 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05574296

Hydrogen's Feasibility and Safety as a Therapy in ECPR

Recruiting
PHASE1All AgesInterventionalTreatment
Boston Children's Hospital
~53 participants
Updated 2025-07-03 on ClinicalTrials.gov
What's tested:HydrogenUsual care

At a glance

Recruiting sites
1 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of hydrogen administration (primary)
Measured over 72 hours
+1 more outcome measured

Conditions

Cardiac Arrest
Extracorporeal Membrane Oxygenation
Reperfusion Injury

Explore related trials

ArrhythmiaCardiac ArrestCongenital Heart DiseaseLiver transplant rejectionMyocarditis

Where it's being run

4 sites across 4 states
District of Columbia1
Massachusetts1
Missouri1
Utah1

Study leadership

  • John N Kheir, MD · PRINCIPAL_INVESTIGATOR · Associate Professor of Pediatrics, Harvard Medical School

Who to contact

John N Kheir, MD
[email protected]
8576368890
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Feasibility of hydrogen administration (primary)72 hours

    Percentage of the first 72 consecutive post-arrest hours (starting at the time of first CPR initiation) in which H2 gas was administered via all of the applicable pathways (e.g. mechanical ventilator and ECMO membrane).

  • Safety of hydrogen administration30 days

    Incidence rate of SAEs of interest per day during the first 30 days post-randomization that have been classified as treatment-related or possibly treatment-related.